488 related articles for article (PubMed ID: 17327489)
1. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
[TBL] [Abstract][Full Text] [Related]
6. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
[TBL] [Abstract][Full Text] [Related]
7. Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Lin LS; Ha S; Ball RG; Tsou NN; Castonguay LA; Doss GA; Fong TM; Shen CP; Xiao JC; Goulet MT; Hagmann WK
J Med Chem; 2008 Apr; 51(7):2108-14. PubMed ID: 18333607
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
Du W; Jewell JP; Lin LS; Colandrea VJ; Xiao JC; Lao J; Shen CP; Bateman TJ; Reddy VB; Ha SN; Shah SK; Fong TM; Hale JJ; Hagmann WK
Bioorg Med Chem Lett; 2009 Sep; 19(17):5195-9. PubMed ID: 19632830
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
[TBL] [Abstract][Full Text] [Related]
10. Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist.
Guan XM; Metzger JM; Yang L; Raustad KA; Wang SP; Spann SK; Kosinski JA; Yu H; Shearman LP; Faidley TD; Palyha O; Kan Y; Kelly TM; Sebhat I; Lin LS; Dragovic J; Lyons KA; Craw S; Nargund RP; Marsh DJ; Strack AM; Reitman ML
J Pharmacol Exp Ther; 2011 Feb; 336(2):356-64. PubMed ID: 21036912
[TBL] [Abstract][Full Text] [Related]
11. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Hagmann WK
Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
[TBL] [Abstract][Full Text] [Related]
12. Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Alig L; Alsenz J; Andjelkovic M; Bendels S; Bénardeau A; Bleicher K; Bourson A; David-Pierson P; Guba W; Hildbrand S; Kube D; Lübbers T; Mayweg AV; Narquizian R; Neidhart W; Nettekoven M; Plancher JM; Rocha C; Rogers-Evans M; Röver S; Schneider G; Taylor S; Waldmeier P
J Med Chem; 2008 Apr; 51(7):2115-27. PubMed ID: 18335976
[TBL] [Abstract][Full Text] [Related]
13. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Addy C; Wright H; Van Laere K; Gantz I; Erondu N; Musser BJ; Lu K; Yuan J; Sanabria-Bohórquez SM; Stoch A; Stevens C; Fong TM; De Lepeleire I; Cilissen C; Cote J; Rosko K; Gendrano IN; Nguyen AM; Gumbiner B; Rothenberg P; de Hoon J; Bormans G; Depré M; Eng WS; Ravussin E; Klein S; Blundell J; Herman GA; Burns HD; Hargreaves RJ; Wagner J; Gottesdiener K; Amatruda JM; Heymsfield SB
Cell Metab; 2008 Jan; 7(1):68-78. PubMed ID: 18177726
[TBL] [Abstract][Full Text] [Related]
14. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.
Wu CH; Hung MS; Song JS; Yeh TK; Chou MC; Chu CM; Jan JJ; Hsieh MT; Tseng SL; Chang CP; Hsieh WP; Lin Y; Yeh YN; Chung WL; Kuo CW; Lin CY; Shy HS; Chao YS; Shia KS
J Med Chem; 2009 Jul; 52(14):4496-510. PubMed ID: 19530697
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys.
Reddy VB; Doss GA; Karanam BV; Samuel K; Lanza TJ; Lin LS; Yu NX; Zhang AS; Raab CE; Stearns RA; Kumar S
Xenobiotica; 2010 Sep; 40(9):650-62. PubMed ID: 20608842
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
Karanam B; Addy C; Bateman T; Reddy VB; Li S; Dean D; Li H; Jones A; Schenk D; Zhang AS; Braun M; Freeman A; Flach S; Stoch A; Chodakewitz J; Wagner JA; Kumar S
Xenobiotica; 2010 Oct; 40(10):691-700. PubMed ID: 20722472
[TBL] [Abstract][Full Text] [Related]
18. Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice.
Kowalski TJ; Spar BD; Weig B; Farley C; Cook J; Ghibaudi L; Fried S; O'Neill K; Del Vecchio RA; McBriar M; Guzik H; Clader J; Hawes BE; Hwa J
Eur J Pharmacol; 2006 Mar; 535(1-3):182-91. PubMed ID: 16540104
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.
Kopka IE; Lin LS; Jewell JP; Lanza TJ; Fong TM; Shen CP; Lao ZJ; Ha S; Castonguay LG; Van der Ploeg L; Goulet MT; Hagmann WK
Bioorg Med Chem Lett; 2010 Aug; 20(16):4757-61. PubMed ID: 20643546
[TBL] [Abstract][Full Text] [Related]
20. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
Mashiko S; Ishihara A; Iwaasa H; Moriya R; Kitazawa H; Mitobe Y; Ito J; Gomori A; Matsushita H; Takahashi T; MacNeil DJ; Van der Ploeg LH; Fukami T; Kanatani A
Obesity (Silver Spring); 2008 Jul; 16(7):1510-5. PubMed ID: 18421274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]